AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22539656 — intervention group
Group type: EXPERIMENTAL
Intervention: Low physical activity
Number of subjects: 385
Study 22539656 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 385
Study 22539656 — intervention group
Group type: EXPERIMENTAL
Intervention: Not being obese
Number of subjects: 385
Study 22539656 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 385
Study 20211908 — intervention group
Group type: EXPERIMENTAL
Intervention: Riluzole (100 mg/day)
Number of subjects: 40
Study 20211908 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 17963858 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraceptive vaginal ring (RING) releasing 15 mcg ethinyl estradiol and 120 mcg etonogestrel per day
Number of subjects: 65
Study 17963858 — intervention group
Group type: COMPARATOR
Intervention: Low-dose oral contraceptive (PILL) containing 20 mcg ethinyl estradiol and 100 mcg levonorgestrel daily
Number of subjects: 65
Study 15859575 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy
Number of subjects: 0
Study 15859575 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11940128 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led counselling service for inflammatory bowel disease patients
Number of subjects: 100
Study 11940128 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 100
Study 10365352 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice weekly supervised oral iron administration (group B)
Number of subjects: 51
Study 10365352 — intervention group
Group type: COMPARATOR
Intervention: Daily unsupervised oral iron administration (group A)
Number of subjects: 51
Study 10365352 — intervention group
Group type: COMPARATOR
Intervention: Parenteral iron (group C)
Number of subjects: 51
Study 10547247 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-lactose formula (LLF, <5% lactose)
Number of subjects: 306
Study 10547247 — intervention group
Group type: COMPARATOR
Intervention: Lactose-containing formula (LCF, 24 kcal/oz)
Number of subjects: 306
Study 2070978 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser
Number of subjects: 91
Study 2070978 — intervention group
Group type: EXPERIMENTAL
Intervention: Heater probe
Number of subjects: 91
Study 2070978 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar electrocoagulation
Number of subjects: 91
Study 6622049 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine-bore suprapubic catheterisation
Number of subjects: 0
Study 6622049 — intervention group
Group type: COMPARATOR
Intervention: Intermittent urethral catheterisation
Number of subjects: 0
Study 30499221 — intervention group
Group type: EXPERIMENTAL
Intervention: qRF‐MRF method
Number of subjects: 5
Study 29806281 — intervention group
Group type: EXPERIMENTAL
Intervention: New anatomical locking plate for sternoclavicular joint (Group A)
Number of subjects: 32
Study 29806281 — intervention group
Group type: COMPARATOR
Intervention: Distal radial T locking plate internal fixation (Group B)
Number of subjects: 32
Study 26773735 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment for standard-risk ALL
Number of subjects: 0
Study 26773735 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified consolidation study arm
Number of subjects: 0
Study 26773735 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age at diagnosis
Number of subjects: 0
Study 25547786 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin-based triple therapy (LAL): levofloxacin 500 mg daily, amoxicillin 1 g b.i.d., lansoprazole 30 mg b.i.d. for 10 days
Number of subjects: 306
Study 25547786 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin-based triple therapy (MAL): moxifloxacin 400 mg daily, amoxicillin 1 g b.i.d., lansoprazole 30 mg b.i.d. for 10 days
Number of subjects: 306
Study 25547786 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (CAL): clarithromycin 500 mg b.i.d., amoxicillin 1 g b.i.d., lansoprazole 30 mg b.i.d.
Number of subjects: 306
Study 22763344 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-channel NIRS with CoG approach during hand movements
Number of subjects: 13
Study 22763344 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-channel NIRS with CoG approach during foot movements
Number of subjects: 13
Study 22763344 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-channel NIRS with CoG approach during rhythmic or discrete hand or foot tapping
Number of subjects: 13
Study 22763344 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-channel NIRS with CoG approach for OHb responses
Number of subjects: 13
Study 20135347 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen
Number of subjects: 500
Study 20135347 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant treatment
Number of subjects: 500
Study 20135347 — intervention group
Group type: EXPERIMENTAL
Intervention: High VEGFR2 expression
Number of subjects: 500
Study 20135347 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR expression and EGFR gene copy number
Number of subjects: 500
Study 18768772 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing word reading ability in 15 at-risk children
Number of subjects: 60
Study 18768772 — intervention group
Group type: COMPARATOR
Intervention: Skilled readers
Number of subjects: 60
Study 18768772 — intervention group
Group type: COMPARATOR
Intervention: Unskilled readers
Number of subjects: 60
Study 15995436 — intervention group
Group type: EXPERIMENTAL
Intervention: Alumina ceramic bearings
Number of subjects: 316
Study 15995436 — intervention group
Group type: COMPARATOR
Intervention: Cobalt chrome-on-polyethylene bearings (Control)
Number of subjects: 316
Study 12207812 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliclazide
Number of subjects: 30
Study 12207812 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide
Number of subjects: 30
Study 10489096 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxonidine
Number of subjects: 77
Study 10489096 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 8942326 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 82
Study 8942326 — intervention group
Group type: COMPARATOR
Intervention: Open cholecystectomy
Number of subjects: 82
Study 1680982 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 120
Study 1680982 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (hydralazine + sorbitrate)
Number of subjects: 120
Study 6210726 — intervention group
Group type: EXPERIMENTAL
Intervention: fenoterol 100 micrograms
Number of subjects: 10
Study 6210726 — intervention group
Group type: EXPERIMENTAL
Intervention: fenoterol 200 micrograms
Number of subjects: 10
Study 6210726 — intervention group
Group type: EXPERIMENTAL
Intervention: fenoterol 50 micrograms combined with 20 micrograms of ipratropium
Number of subjects: 10
Study 6210726 — intervention group
Group type: EXPERIMENTAL
Intervention: fenoterol 100 micrograms combined with 40 micrograms of ipratropium
Number of subjects: 10
Study 6210726 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 micrograms of ipratropium
Number of subjects: 10
Study 6210726 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study 31096990 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-specific drill template (PDT)
Number of subjects: 10
Study 31096990 — intervention group
Group type: COMPARATOR
Intervention: Freehand group
Number of subjects: 10
Study 28183355 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) - 2000 pulses of 1‐Hz TMS for 10 consecutive business days
Number of subjects: 35
Study 28183355 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS)
Number of subjects: 35
Study 26530645 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly cross-linked polyethylene (XLPE)
Number of subjects: 100
Study 26530645 — intervention group
Group type: COMPARATOR
Intervention: Moderately cross-linked then annealed polyethylene
Number of subjects: 100
Study 23422463 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality-based cognitive rehabilitation program (12 sessions)
Number of subjects: 37
Study 21157365 — intervention group
Group type: COMPARATOR
Intervention: 23 mm cryoballoon
Number of subjects: 8
Study 21157365 — intervention group
Group type: EXPERIMENTAL
Intervention: 28 mm cryoballoon
Number of subjects: 8
Study 19824225 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive early intervention programme (OPUS)
Number of subjects: 547
Study 19824225 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 547
Study 17542352 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic oral solution of risperidone (1 mg)
Number of subjects: 32
Study 17542352 — intervention group
Group type: COMPARATOR
Intervention: Risperdal tablets (1 mg)
Number of subjects: 32
Study 15356547 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to tobacco smoke (measured by urinary cotinine)
Number of subjects: 368
Study 15356547 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms of asthma
Number of subjects: 368
Study 15356547 — intervention group
Group type: EXPERIMENTAL
Intervention: Nighttime asthma symptoms
Number of subjects: 368
Study 15356547 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen sensitization (measured by skin prick test)
Number of subjects: 368
Study 15356547 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication treatment for asthma
Number of subjects: 368
Study 15356547 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall asthma control
Number of subjects: 368
Study 12297482 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral nutrition supplemented with 20 g/d L-arginine for 7 days
Number of subjects: 40
Study 12297482 — intervention group
Group type: COMPARATOR
Intervention: Standard parenteral nutrition
Number of subjects: 40
Study 9708936 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy supported with G‐CSF (5 microg/kg subcutaneously on Days 2‐13; Arm B)
Number of subjects: 80
Study 9708936 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (Arm A)
Number of subjects: 80
Study 9708936 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy supported with G‐CSF (Arm B)
Number of subjects: 80
Study 8110580 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral ilioinguinal nerve block
Number of subjects: 62
Study 8110580 — intervention group
Group type: EXPERIMENTAL
Intervention: Wound infiltration with 0.5% bupivacaine
Number of subjects: 62
Study 8110580 — intervention group
Group type: COMPARATOR
Intervention: Control group (no local anaesthetic supplementation)
Number of subjects: 62
Study 1710099 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid 5-hydroxyindoleacetic acid levels in long-term weight-restored anorectic subjects
Number of subjects: 32
Study 1710099 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid homovanillic acid levels in long-term weight-restored anorectic subjects
Number of subjects: 32
Study 1710099 — intervention group
Group type: COMPARATOR
Intervention: Cerebrospinal fluid 5-hydroxyindoleacetic acid levels in controls
Number of subjects: 32
Study 10249189 — intervention group
Group type: EXPERIMENTAL
Intervention: Empathy training
Number of subjects: 0
Study 10249189 — intervention group
Group type: COMPARATOR
Intervention: No training (Control)
Number of subjects: 0
Study 31448382 — intervention group
Group type: EXPERIMENTAL
Intervention: Live Artemia nauplii + 0‰ salinity
Number of subjects: 5
Study 31448382 — intervention group
Group type: EXPERIMENTAL
Intervention: Live Artemia nauplii + 2‰ salinity
Number of subjects: 5
Study 31448382 — intervention group
Group type: EXPERIMENTAL
Intervention: Frozen Artemia nauplii + 0‰ salinity
Number of subjects: 5
Study 31448382 — intervention group
Group type: EXPERIMENTAL
Intervention: Frozen Artemia nauplii + 2‰ salinity
Number of subjects: 5
Study 30487231 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclisiran
Number of subjects: 501
Study 30487231 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 501
Study 28236469 — intervention group
Group type: EXPERIMENTAL
Intervention: Grass allergen peptide 8x6Q2W
Number of subjects: 282
Study 28236469 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 282
Study 26542494 — intervention group
Group type: EXPERIMENTAL
Intervention: Impella 2.5 (registry patients)
Number of subjects: 637
Study 26542494 — intervention group
Group type: COMPARATOR
Intervention: Impella 2.5 (PROTECT II trial patients)
Number of subjects: 637
Study 23820174 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant FXIII 17.5 IU/kg
Number of subjects: 409
Study 23820174 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant FXIII 35 IU/kg
Number of subjects: 409
Study 23820174 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 409
Study 22688890 — intervention group
Group type: EXPERIMENTAL
Intervention: HRV-biofeedback (12 sessions)
Number of subjects: 56
Study 22688890 — intervention group
Group type: COMPARATOR
Intervention: Craving-control (no intervention)
Number of subjects: 56
Study 22688890 — intervention group
Group type: COMPARATOR
Intervention: Non-craving-control (no intervention)
Number of subjects: 56
Study 19481229 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine (118 mL daily for 6 months)
Number of subjects: 24
Study 19481229 — intervention group
Group type: COMPARATOR
Intervention: White wine (118 mL daily for 6 months)
Number of subjects: 24
Study 19481229 — intervention group
Group type: COMPARATOR
Intervention: Control group (no wine)
Number of subjects: 24
Study 17532935 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung-volume reduction surgery
Number of subjects: 23
Study 15592949 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA measurement (n = 3,562, group 1)
Number of subjects: 7124
Study 15592949 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 3,562, group 2)
Number of subjects: 7124
Study 11310304 — intervention group
Group type: EXPERIMENTAL
Intervention: Antitachycardia pacing (ATP) with a single burst (8 or 16 stimuli)
Number of subjects: 20
Study 11310304 — intervention group
Group type: COMPARATOR
Intervention: Cardioversion (defibrillation threshold plus 10 J)
Number of subjects: 20
Study 9599103 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban plus heparin
Number of subjects: 1915
Study 9599103 — intervention group
Group type: COMPARATOR
Intervention: Heparin alone
Number of subjects: 1915
Study 7974677 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg chlorproguanil daily
Number of subjects: 156
Study 7974677 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg proguanil daily
Number of subjects: 156
Study 7974677 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg chlorproguanil weekly
Number of subjects: 156
Study 7974677 — intervention group
Group type: COMPARATOR
Intervention: 100 mg calcium lactate weekly (placebo)
Number of subjects: 156
Study 2686567 — intervention group
Group type: EXPERIMENTAL
Intervention: Nissen fundoplication
Number of subjects: 31
Study 2686567 — intervention group
Group type: COMPARATOR
Intervention: Modified Toupet semifundoplication
Number of subjects: 31
Study 409052 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate 10 mg, four times a day
Number of subjects: 17
Study 409052 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 31860534 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Citrulline (CIT) 6 g·d for 7 days
Number of subjects: 9
Study 31860534 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Citrulline (CIT)
Number of subjects: 9
Study 31860534 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin placebo (PLAC)
Number of subjects: 9
Study 30971596 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate infusion at 15 mg/kg/h
Number of subjects: 122
Study 30971596 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 122
Study 28814398 — intervention group
Group type: EXPERIMENTAL
Intervention: MedDiet + EVOO
Number of subjects: 983
Study 28814398 — intervention group
Group type: EXPERIMENTAL
Intervention: MedDiet + nuts
Number of subjects: 983
Study 28814398 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 983
Study 25704049 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle guide-assisted (NG) technique
Number of subjects: 36
Study 25704049 — intervention group
Group type: COMPARATOR
Intervention: Conventional freehand (FH) technique
Number of subjects: 36
Study 23106253 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased TpTe/QT ratio (0.24 ± 0.03 ms)
Number of subjects: 128
Study 23106253 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased TpTe (105.56 ± 20.36 ms)
Number of subjects: 128
Study 23106253 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased TpTe/QT ratio (0.22 ± 0.04)
Number of subjects: 128
Study 23106253 — intervention group
Group type: COMPARATOR
Intervention: QT interval
Number of subjects: 128
Study 23106253 — intervention group
Group type: EXPERIMENTAL
Intervention: TpTe/QT ratio ≥ 0.25
Number of subjects: 128
Study 21723750 — intervention group
Group type: EXPERIMENTAL
Intervention: WF10 (Immunokine)
Number of subjects: 40
Study 21723750 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 19186971 — intervention group
Group type: EXPERIMENTAL
Intervention: Submerged implants
Number of subjects: 0
Study 19186971 — intervention group
Group type: COMPARATOR
Intervention: Non-submerged implants
Number of subjects: 0
Study 17075109 — intervention group
Group type: EXPERIMENTAL
Intervention: Palifermin (40 microg/kg for 3 consecutive days)
Number of subjects: 64
Study 17075109 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 17075109 — intervention group
Group type: EXPERIMENTAL
Intervention: Palifermin
Number of subjects: 64
Study 17075109 — intervention group
Group type: COMPARATOR
Intervention: Palifermin and Placebo
Number of subjects: 64
Study 14970775 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 40
Study 14970775 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% mepivacaine
Number of subjects: 40
Study 14970775 — intervention group
Group type: COMPARATOR
Intervention: Topical anesthetic gel
Number of subjects: 40
Study 14970775 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 40
Study 11360129 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene (42 mg)
Number of subjects: 1431
Study 11360129 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A (7000 microg RE)
Number of subjects: 1431
Study 11360129 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1431
Study 9245870 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin administered to half the patients at the start of the procedure
Number of subjects: 60
Study 9245870 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 60
Study 8506518 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 20
Study 8506518 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 3102754 — intervention group
Group type: EXPERIMENTAL
Intervention: TPN supplementation
Number of subjects: 28
Study 3102754 — intervention group
Group type: COMPARATOR
Intervention: No TPN supplementation (Control)
Number of subjects: 28
Study 31478756 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual arousal condition in Study 1
Number of subjects: 290
Study 31478756 — intervention group
Group type: EXPERIMENTAL
Intervention: Disgust condition in Study 2
Number of subjects: 290
Study 31478756 — intervention group
Group type: COMPARATOR
Intervention: Control condition in Study 1
Number of subjects: 290
Study 31478756 — intervention group
Group type: COMPARATOR
Intervention: Control condition in Study 2
Number of subjects: 290
Study 30354397 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 therapy (4 mg/d for 310±87 days)
Number of subjects: 166
Study 30354397 — intervention group
Group type: COMPARATOR
Intervention: Control group (observed for 302±102 days)
Number of subjects: 166
Study 30354397 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 therapy
Number of subjects: 166
Study 30354397 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 166
Study 27406347 — intervention group
Group type: EXPERIMENTAL
Intervention: Veliparib-Carboplatin
Number of subjects: 72
Study 27406347 — intervention group
Group type: COMPARATOR
Intervention: Control Therapy
Number of subjects: 72
Study 24968280 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid protein snack containing 30 g carbohydrates and 30 g proteins (casein, whey protein or an equal mix of the two; n 26-28 per group)
Number of subjects: 82
Study 24968280 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid protein snack (casein, whey protein or an equal mix)
Number of subjects: 82
Study 24968280 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid protein snack
Number of subjects: 82
Study 24968280 — intervention group
Group type: COMPARATOR
Intervention: Control snack containing 60 g maltodextrin
Number of subjects: 82
Study 22440090 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) augmented with information provision and behavioral skills building based on the IMB model
Number of subjects: 250
Study 20505049 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin infiltration (Icon, pre‐product; DMG)
Number of subjects: 22
Study 20505049 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 22
Study 20633375 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor Cortex Stimulation (MCS) ON
Number of subjects: 10
Study 20633375 — intervention group
Group type: COMPARATOR
Intervention: Motor Cortex Stimulation (MCS) OFF
Number of subjects: 10
Study 20633375 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor Cortex Stimulation (MCS)
Number of subjects: 10
Study 17253121 — intervention group
Group type: EXPERIMENTAL
Intervention: 2D and 3D intracardiac echocardiography (ICE)
Number of subjects: 32
Study 12814458 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliclazide 80 mg BID for 4 weeks
Number of subjects: 0
Study 12814458 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride 2 mg OD for 4 weeks
Number of subjects: 0